DAC linker is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
=== Teat flow rate === Teat characteristics can also have important implications for infant's sucking pattern and milk intake. Milk flow rate is defined as "the rate at which milk moves from the bottle nipple into the infant's mouth during bottle-feeding." Characteristics such as the shape of the nipple and the way it is perforated may impact flow rate and the coordination of sucking, swallowing and breathing during feeding. Unfortunately, categorization and labeling of teats to indicate flow rate is neither standardized nor consistent. There is significant variability between and within brands and models. In one study, nipples labeled "Slow" or "Newborn" (0–3 months) had flow rates ranging from 1.68 mL/min to 15.12 mL/min."The name assigned to the nipple type does not provide clear information to parents attempting to choose a nipple". This may be of extra concern in the case of fragile infants. Specialized teats are available for infants with cleft palate.
A successful DNA extraction will yield a DNA sample with long, non-degraded strands. A successful RNA extraction will yield a RNA sample that should be converted to complementary DNA (cDNA) using reverse transcriptase—a Reverse transcriptase synthesizes a double-stranded complementary DNA based on existing strands of RNA, and the resulting cDNA pool can be sequenced. This reaction is typically primed using random hexamers, or primers that target the mRNA poly(A) tail. cDNA can then be processed the same way as genomic DNA. After DNA or RNA extraction, samples may require further preparation depending on the sequencing method. For Sanger sequencing, either cloning procedures or PCR are required prior to sequencing. In the case of next-generation sequencing methods, library preparation is required before processing. Assessing the quality and quantity of nucleic acids both after extraction and after library preparation identifies degraded, fragmented, and low-purity samples and yields high-quality sequencing data.
=== Fatty acid synthesis === In previous stages acetyl-CoA is transferred from the mitochondria to the cytoplasm where fatty acid synthase resides. The acetyl-CoA is transported as a citrate, which has been previously formed in the mitochondrial matrix from acetyl-CoA and oxaloacetate. This reaction usually initiates the citric acid cycle, but when there is no need of energy it is transported to the cytoplasm where it is broken down to cytoplasmic acetyl-CoA and oxaloacetate. Another part of the cycle requires NADPH for the synthesis of fatty acids. Part of this reducing power is generated when the cytosolic oxaloacetate is returned to the mitochondria as long as the internal mitochondrial layer is non-permeable for oxaloacetate. Firstly the oxaloacetate is reduced to malate using NADH. Then the malate is decarboxylated to pyruvate. Now this pyruvate can easily enter the mitochondria, where it is carboxylated again to oxaloacetate by pyruvate carboxylase. In this way, the transfer of acetyl-CoA that is from the mitochondria into the cytoplasm produces a molecule of NADH. The overall reaction, which is spontaneous, may be summarized as:
Sources: en.wikipedia.org
=== Block === In most US cities, a city block is between 1⁄16 and 1⁄8 mi (100 and 200 m). In Manhattan, the measurement "block" usually refers to a north–south block, which is 1⁄20 mi (80 m). Sometimes people living in places (like Manhattan) with a regularly spaced street grid will speak of long blocks and short blocks. Within a typical large North American city, it is often only possible to travel along east–west and north–south streets, so travel distance between two points is often given in the number of blocks east–west plus the number north–south (known to mathematicians as the Manhattan distance).
Long-chain-fatty-acid—CoA ligase catalyzes the reaction between a fatty acid with ATP to give a fatty acyl adenylate, plus inorganic pyrophosphate, which then reacts with free coenzyme A to give a fatty acyl-CoA ester and AMP. If the fatty acyl-CoA has a long chain, then the carnitine shuttle must be utilized (shown in the table below): Acyl-CoA is transferred to the hydroxyl group of carnitine by carnitine palmitoyltransferase I, located on the cytosolic faces of the outer and inner mitochondrial membranes. Acyl-carnitine is shuttled inside by a carnitine-acylcarnitine translocase, as a carnitine is shuttled outside. Acyl-carnitine is converted back to acyl-CoA by carnitine palmitoyltransferase II, located on the interior face of the inner mitochondrial membrane. The liberated carnitine is shuttled back to the cytosol, as an acyl-carnitine is shuttled into the matrix. If the fatty acyl-CoA contains a short chain, these short-chain fatty acids can simply diffuse through the inner mitochondrial membrane.
== Description == The cap of this mushroom grows up to 8–30 cm (3–12 in) wide, sometimes more. Viscid when moist, the cap is convex when young and flattens with age. The colour is generally reddish-brown, sometimes with a paler margin. The stipe grows up to 8–25 cm (3–10 in) tall and 2–7 cm (1–3 in) thick—rather large in comparison to the cap. The stem is usually enlarged at the base when young, becoming more cylindrical in age. It is finely reticulate on the upper portion or sometimes the whole. The flesh of the stem is sometimes dark yellow near the base. The undersurface of the cap consists of thin tubes, the site of spore production; they are 1 to 2 cm (1⁄2 to 3⁄4 in) deep, and whitish in colour when young, but mature to a greenish-yellow. The angular pores, which do not stain when bruised, are small—roughly 2 to 3 pores per millimetre. In youth, the pores are white and appear as if stuffed with cotton (which are actually mycelia); as they age, they change colour to yellow and later to brown. The spore print is olive brown. The flesh of the fruit body is white, thick and firm when young, but becomes somewhat spongy with age. When bruised or cut, it either does not change colour, or turns a very light brown or light red. Mature specimens can weigh about 1 kg (2 lb 3 oz). A huge specimen collected on the Isle of Skye, Scotland, in 1995 weighed 3.2 kg (7 lb 1 oz); its cap was 42 cm (16+1⁄2 in) wide and the stipe was 18 cm (7 in) tall and 14 cm (5+1⁄2 in) wide. A similarly sized specimen found in Poland in 2013 made international news.
Sources: en.wikipedia.org
== Etymology == While exploring inland along the northern coast of Florida in 1528, the members of the Narváez expedition, including Álvar Núñez Cabeza de Vaca, found a Native American village near present-day Tallahassee, Florida, the name of which they transcribed as Apalchen or Apalachen (Apalachee pronunciation: [a.paˈla.tʃɛn]). The name was soon altered by the Spanish to Apalachee and used as a name for the tribe and region spreading well inland to the north. Pánfilo de Narváez's expedition first entered Apalachee territory on June 15, 1528, and applied the name. Now spelled "Appalachian", it is the fourth-oldest surviving European place-name in the US. After the 1540 expedition of Hernando de Soto, Spanish cartographers began to apply the name of the tribe to the mountains themselves. The first cartographic appearance of Apalchen is on Diego Gutiérrez's map of 1562; the first use for the mountain range is the map of Jacques le Moyne de Morgues in 1565.
A varied diet is very important to the dwarf gourami, which is an omnivore that prefers both algae-based foods and meaty foods. An algae-based flake food, along with freeze-dried bloodworms, tubifex, and brine shrimp, will provide these fish with proper nutrition.
Protons are spin-1/2 fermions and are composed of three valence quarks, making them baryons (a sub-type of hadrons). The two up quarks and one down quark of a proton are held together by the strong force, mediated by gluons. A modern perspective has a proton composed of the valence quarks (up, up, down), the gluons, and transitory pairs of sea quarks. Protons have a positive charge distribution, which decays approximately exponentially, with a root mean square charge radius of about 0.8 fm. Protons and neutrons are both nucleons, which may be bound together by the nuclear force to form atomic nuclei. The nucleus of the most common isotope of the hydrogen atom (with the chemical symbol "H") is a lone proton. The nuclei of the heavy hydrogen isotopes deuterium and tritium contain one proton bound to one and two neutrons, respectively. All other types of atomic nuclei are composed of two or more protons and various numbers of neutrons.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.